| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Rob Bresnahan PA08 | 1 | 1 | +$24.5K | Sold May 15, 25 |
| Jefferson Shreve IN06 | 1 | 1 | +$0 | Sold May 12, 25 |
| Julie Johnson TX32 | 1 | +$8.0K | Bought Jan 15, 25 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| May 15, 25 | Rob Bresnahan PA08 | Self | Sell | $1,001 - $15,000 | May 31, 25 (16d) | |
| May 12, 25 | Jefferson Shreve IN06 | Self | Sell | $15,001 - $50,000 | Jun 22, 25 (41d) | |
| May 8, 25 | Jefferson Shreve IN06 | Self | Buy | $15,001 - $50,000 | Jun 22, 25 (45d) | |
| Apr 8, 25 | Rob Bresnahan PA08 | Self | Buy | $15,001 - $50,000 | May 8, 25 (30d) | |
| Jan 15, 25 | Julie Johnson TX32 | Joint | Buy | $1,001 - $15,000 | Feb 12, 25 (28d) |
From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 4, 2026 | Parisotto Shannon MOfficer | Sale at price 308.44 per share. | 981 | $302.58K |
| Oct 4, 2026 | Parisotto Shannon MOfficer | Conversion of Exercise of derivative security at price 208.44 per share. | 981 | $204.48K |
| Aug 24, 2026 | Foster James CDirector | Sale at price 300.00 per share. | 33.6K | $10.07M |
| Aug 24, 2026 | Foster James CDirector | Conversion of Exercise of derivative security at price 194.12 - 208.44 per share. | 33.6K | $6.69M |
| Aug 18, 2026 | Girshick BirgitChief Executive Officer | Stock Gift at price 0.00 per share. | 528 | — |
| Aug 18, 2026 | Parisotto Shannon MOfficer | Sale at price 294.12 per share. | 2K | $599.71K |
| Aug 18, 2026 | Parisotto Shannon MOfficer | Conversion of Exercise of derivative security at price 194.12 per share. | 2K | $395.81K |
| Aug 17, 2026 | Andrews Nancy CDirector | Sale at price 285.24 per share. | 573 | $163.44K |
| Aug 17, 2026 | Andrews Nancy CDirector | Conversion of Exercise of derivative security at price 164.30 per share. | 573 | $94.14K |
| Aug 10, 2026 | Parisotto Shannon MOfficer | Sale at price 279.66 per share. | 3.7K | $1.04M |
| Aug 10, 2026 | Girshick BirgitChief Executive Officer | Sale at price 279.90 per share. | 6.5K | $1.82M |
| Aug 10, 2026 | Girshick BirgitChief Executive Officer | Conversion of Exercise of derivative security at price 179.66 per share. | 6.5K | $1.17M |
| Aug 10, 2026 | Parisotto Shannon MOfficer | Conversion of Exercise of derivative security at price 179.66 per share. | 3.7K | $667.26K |
| Aug 9, 2026 | Laplume Joseph WOfficer | Stock Gift at price 0.00 per share. | 257 | — |
| Aug 9, 2026 | Foster James CDirector | Sale at price 275.00 per share. | 28.7K | $7.90M |
| Aug 9, 2026 | Foster James CDirector | Conversion of Exercise of derivative security at price 179.66 per share. | 28.7K | $5.16M |
| Aug 5, 2026 | Knell Michael GunnarOfficer | Sale at price 258.53 - 265.17 per share. | 6.6K | $1.73M |
| Aug 5, 2026 | Creamer Victoria LOfficer | Sale at price 259.16 per share. | 4.2K | $1.08M |
| Aug 5, 2026 | Knell Michael GunnarOfficer | Conversion of Exercise of derivative security at price 179.66 - 208.44 per share. | 2.3K | $459.91K |
| Aug 5, 2026 | Creamer Victoria LOfficer | Conversion of Exercise of derivative security at price 179.66 per share. | 4.2K | $750.80K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 5.5 | -15.2 | -3.4 | -3.2 | 8.2 | 25.5 | 2.5 | 24.0 | 2.3 | 2.3 | +51.3% | ||
| 2025 | -10.7 | 0.3 | -8.9 | -21.2 | 14.3 | 11.9 | 11.8 | -3.7 | -4.2 | 15.1 | -1.1 | 12.0 | +8.1% |
| 2024 | -8.5 | 17.5 | 6.6 | -15.5 | -9.0 | -0.9 | 18.2 | -19.0 | -0.4 | -9.3 | 11.5 | -7.3 | −21.9% |
| 2023 | 11.6 | -9.8 | -8.0 | -5.8 | 1.7 | 8.7 | -0.3 | -1.3 | -5.2 | -14.1 | 17.1 | 20.0 | +8.5% |
| 2022 | -12.5 | -11.7 | -2.5 | -15.0 | -3.1 | -8.6 | 17.1 | -18.1 | -4.1 | 7.9 | 7.7 | -4.7 | −42.2% |
| 2021 | 3.7 | 10.5 | 1.3 | 14.7 | 1.7 | 9.4 | 10.0 | 9.1 | -7.0 | 8.7 | -18.5 | 3.0 | +50.8% |
| 2020 | 1.2 | 0.6 | -18.9 | 14.6 | 24.2 | -3.0 | 14.1 | 10.0 | 3.4 | 0.6 | 3.0 | 6.5 | +63.6% |
| 2019 | 8.8 | 15.4 | 2.2 | -3.3 | -10.7 | 13.1 | -5.2 | -2.5 | 0.9 | -1.8 | 11.7 | 5.2 | +35.0% |
| 2018 | -3.7 | 1.1 | 0.1 | -2.4 | 3.2 | 4.4 | 10.7 | -0.6 | 8.9 | -9.5 | 10.7 | -16.1 | +3.4% |
| 2017 | 6.1 | 7.6 | 3.4 | -0.3 | 2.6 | 9.9 | -2.9 | 10.8 | -0.7 | 7.7 | -10.4 | 5.0 | +43.7% |
| 2016 | -7.7 | -1.1 | 3.4 | 4.4 | 8.4 | -4.1 | 6.7 | -5.4 | 0.2 | -9.0 | -6.3 | 7.2 | −5.2% |
| 2015 | 9.0 | 10.6 | 3.4 | -12.8 | 4.6 | -2.8 | 10.3 | -11.2 | -7.8 | 2.7 | 17.4 | 5.0 | +26.3% |
| 2014 | 6.6 | 5.1 | 1.6 | -11.0 | -0.3 | -0.1 | 1.3 | 9.0 | 1.1 | 5.7 | 2.5 | -1.7 | +20.0% |
| 2013 | 10.3 | -1.4 | 8.7 | -1.8 | -0.4 | -5.3 | 11.0 | 1.1 | 0.5 | 6.4 | 6.0 | 1.7 | +41.6% |
| 2012 | 23.6 | 4.0 | 2.7 | -1.6 | -6.1 | -1.9 | 3.9 | 6.7 | 9.0 | -5.8 | 2.8 | -2.3 | +37.1% |
| 2011 | 7.9 | -5.0 | 5.3 | 9.9 | -8.3 | 5.1 | -2.7 | -16.3 | -13.6 | 12.8 | -12.2 | -3.6 | −23.1% |
| 2010 | 7.9 | 4.3 | 3.7 | -14.8 | 0.2 | 2.0 | -9.1 | -9.1 | 17.3 | -1.1 | -0.4 | 8.9 | +5.5% |
| 2009 | -6.8 | 1.6 | 9.7 | 1.6 | 13.7 | 7.4 | -2.0 | 4.3 | 7.2 | -1.2 | -12.0 | 4.8 | +28.6% |
| 2008 | -5.3 | -6.0 | 0.6 | -1.5 | 10.7 | -0.6 | 4.0 | -1.3 | -15.4 | -35.5 | -36.4 | 14.9 | −60.2% |
| 2007 | 4.0 | 1.9 | 0.9 | 2.4 | 12.3 | -2.9 | -0.9 | 2.5 | 7.0 | 3.3 | 9.5 | 3.6 | +52.1% |
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Buy / hold / sell counts